At first glance, there is positive news. The two most recent annual reports from the American Cancer Society show consecutive improvements in cancer survival for the first time.
Our deepening understanding of genomics is revolutionizing cancer care and driving the creation of new, potentially curative treatments for cancers that would have proved fatal less than a decade ago. We continue to expand our arsenal of targeted anti-cancer medications and cell-based immune-oncologic therapeutics, pushing the boundaries of what is possible for patients at a previously unimaginable pace.
But even with these advances and recent expansions in health care coverage, far too many patients lack appropriate access to optimal treatments, excluding them from these revolutionary developments in cancer care.
Read Full Article »